MIRT Ireland announce a new joint US-Ireland clinic trial-the “RVD-SC Trial”

MIRT Ireland are delighted to announce a new joint US-Ireland clinic trial-the “RVD-SC Trial” combining our best available drugs for Multiple Myeloma patients. Dr O Gorman in Ireland/Europe and Prof Paul Richardson in the US are the co-Principal Investigators. The trial will be run by the Irish Clinical Oncology Research Group in Ireland and the Dana Farber Cancer Institute in Boston. The phase 2 trial is co-funded by major international pharmaceutical companies Celgene, Janssen and Millennium.

“We hope the RVD-SC Trial will be a ground-breaking trial that will combine best response with lowest side effects” say Dr O’Gorman and Prof Richardson in a joint statement.

It is expected the trial will open before the end of 2013.

« Back